Table 1.
Variable | SLE patients |
---|---|
Gender (female/male, n) | 76/14 |
Age (mean ± SD, year) | 33.1 ± 9.8 |
Disease duration (mean ± SD, days) | 72.0 ± 53.0 |
SLEDAI (mean ± SD) | 12.9 ± 7.9 |
Disease activity | |
SLEDAI ≤ 8, (n, %) | 40, (44.4) |
SLEDAI > 8, (n, %) | 50, (55.6) |
Disease manifestations | |
Arthritis (n, %) | 41, (45.6) |
Rash (n, %) | 43, (47.8) |
Oral ulcer (n, %) | 11, (5.0) |
Serositis (n, %) | 16, (17.8) |
Photosensitivity (n, %) | 14, (15.6) |
Raynaud’s phenomenon (n, %) | 5, (5.6) |
Hematological (n, %) | 46, (51.1) |
Lupus nephritis (proteinuria ≥ 0.5 g/24 h) (n, %) | 21, (23.3) |
Neuropsychiatric manifestations (n, %) | 8, (8.9) |
Autoantibody profile | |
Anti-dsDNA + (n, %) | 75, (83.3) |
Anti-Sm + (n, %) | 21, (23.3) |
Anti-SSA + (n, %) | 42, (46.7) |
Anti-SSB + (n, %) | 13, (14.4) |
Anti-U1RNP + (n, %) | 29, (32.2) |
Anti-Rib-P + (n, %) | 15, (16.7) |
Anti-nucleosome-A + (n, %) | 36, (40.0) |
SLE systemic lupus erythematosus, SD standard deviation, SLEDAI-2 K SLE disease activity index 2000